Amgen just got one step closer to bringing its monthly weight loss drug to market
Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.
The pharma company announced today that it has begun two late-stage clinical trials for its experimental weight-loss drug, MariTide. If successful, MariTide could disrupt the market by offering a less frequent dosing regimen than the current weekly injections on the market. The drug has been tested as a once-monthly treatment, as well as with dosing intervals of every other month and once every three months.
Amgen's chief scientific officer, Jay Bradner, shared key details of the new trials Wednesday morning at TD Cowen's annual healthcare conference.
The two trials will enroll about 4,500 patients in total. One study will recruit 3,500 participants that are obese or overweight, while the other will include 999 people who are both obese or overweight and have type 2 diabetes.
The primary objective of both studies is to assess the percentage of weight loss at 72 weeks. Amgen will test three dose levels — low, medium, and high — starting patients at a lower dose and gradually increasing it to the target doses. According to ClinicalTrials.gov, the studies are set to begin officially on March 17 and are expected to conclude in early 2027.
In November, the company reported that MariTide helped patients with obesity or excess weight shed an average of 20% of their body weight in an earlier 52-week trial. For comparison, the highest dose of Wegovy resulted in an average weight loss of 15% after 68 weeks in clinical trials. Meanwhile, patients taking the highest dose of Eli Lilly's rival drug, Zepbound, achieved over 20% weight loss after 72 weeks.
For the latest news, Facebook, Twitter and Instagram.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Eli Lilly (NYSE:LLY) lands an $870 million pact with Camurus (CAMX) to build long-acting obesity treatments, tapping FluidCrystalslow-release tech to stretch dosing from days to weeks. Lilly's team will work hand-in-glove with Camurus engineers, adapting the gel-matrix delivery platformalready proven in other therapiesto Lilly's top weight-loss candidates, including Zepbound. Instead of daily or weekly shots, patients could look forward to a monthly injection or even a once-daily pill that behaves like a slow-release depot. The deal kicks off with an upfront payment and scales into development and commercialization milestones, keeping Lilly's risk in check while aligning both firms on successful trial readouts. This move comes as Lilly races against rivals in the booming obesity marketnow set to exceed $50 billion by 2030and follows its own push for an oral GLP-1 option to rival injectables. By offering less-frequent dosing, Lilly hopes to tackle patient drop-off and win market share from peers like Novo Nordisk. Plus, the modified release format could open doors to new payer contracts, since fewer doses often translate to better adherence and lower overall costs. Why It Matters: Extended-release obesity drugs could revolutionize treatment by cutting patient burden and boosting lifetime revenue. Lilly's bet on Camurus' delivery system underscores its commitment to leading the metabolic disease space rather than just competing on molecule potency. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Eli Lilly (NYSE:LLY) lands an $870 million pact with Camurus (CAMX) to build long-acting obesity treatments, tapping FluidCrystalslow-release tech to stretch dosing from days to weeks. Lilly's team will work hand-in-glove with Camurus engineers, adapting the gel-matrix delivery platformalready proven in other therapiesto Lilly's top weight-loss candidates, including Zepbound. Instead of daily or weekly shots, patients could look forward to a monthly injection or even a once-daily pill that behaves like a slow-release depot. The deal kicks off with an upfront payment and scales into development and commercialization milestones, keeping Lilly's risk in check while aligning both firms on successful trial readouts. This move comes as Lilly races against rivals in the booming obesity marketnow set to exceed $50 billion by 2030and follows its own push for an oral GLP-1 option to rival injectables. By offering less-frequent dosing, Lilly hopes to tackle patient drop-off and win market share from peers like Novo Nordisk. Plus, the modified release format could open doors to new payer contracts, since fewer doses often translate to better adherence and lower overall costs. Why It Matters: Extended-release obesity drugs could revolutionize treatment by cutting patient burden and boosting lifetime revenue. Lilly's bet on Camurus' delivery system underscores its commitment to leading the metabolic disease space rather than just competing on molecule potency. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
'RHONJ''s Dolores Catania Says She Gained 20 Lbs. After Mounjaro ‘Stopped Working': ‘I'm Having a Really Hard Time'
Dolores Catania revealed she gained 20 lbs. after her Mounjaro 'stopped working' The RHONJ star she's 'having a really hard time' dealing with the weight gain She admitted that there's a possibility her weight gain could be due to the slew of heart medications she's been takingDolores Catania is struggling with weight gain even while taking Mounjaro. On June 6, the Real Housewives of New Jersey star, 54, appeared on SiriusXM's Jeff Lewis Live and talked about taking Mounjaro, an FDA-approved prescription medication for people with type 2 diabetes. It's a brand name for tirzepatide, which is highly effective for weight loss by reducing appetite and improving how the body breaks down sugar and fat. Mounjaro is similar to Ozempic and Wegovy — brand names for semaglutide. They work in the brain to impact satiety and have been trending in and out of Hollywood. Catania — who previously shared that she lost 20 lbs. with the medication — revealed on the show that she's now gained the weight back. 'I'm having a really hard time right now. My Mounjaro stopped working, I gained 20 lbs.,' she shared. 'I've been looking for therapy for all my friends. I'm really having a bad time with this.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Lewis asked if she's able to switch to another medication like Ozempic and she immediately replied, 'I did it all.' Catania said she has since stopped taking the medication for about a month because she needed to undergo a cardiac ablation — a minimally invasive procedure where doctors freeze or burn the inside of the heart to restore a normal heart rhythm. The Bravo star assured that she's 'fine' now and was only in the hospital for the procedure. 'I'm on a bunch of medicine, like, 10 pills a day,' she said. 'It's just a formality now. I have to take it for the next 90 days, then I should be done.' 'Maybe that's why I gained weight,' she said of all the new medications. 'I'm hoping maybe that's why.' ! is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! Catania previously spoke about her success on Mounjaro in 2023. "I'm down 20 pounds," she told The U.S. Sun, adding that her goal weight "is to be in the low 130s." The reality star admitted that she was previously 'gaining weight every month' and got up to 163 lbs. before trying the medication and seeing some results. 'It doesn't happen overnight. It doesn't come off easy," she said. Catania was originally prescribed Ozempic, taking the drug for two years before switching to Mounjaro in early 2023. 'I was medically prescribed for both because I am insulin resistant/pre-diabetic and have a thyroid issue,' she said at the time. Catania stressed that although she was still hoping to lose more weight on Mounjaro, taking these medications isn't a quick fix to weight loss, insisting that she focuses on exercising, healthy eating, and limiting her drinking — minus the wild nights spent with her RHONJ castmates. "I stopped taking [Ozempic] because it was expensive and everything. But being healthy and living a healthy lifestyle is cheap — it's free!" she told the outlet. "I work out regularly. There is no easy fix for weight loss and I have to watch what I eat." Read the original article on People
